0
Signin
countryflagUK

8082-737-676

0R15 8539.0 2.1534% 0R1E 8600.0 3.3654% 0M69 None None% 0R2V 190.25 -0.1312% 0QYR 1345.5 2.0871% 0QYP 424.0 0.5931% 0LCV 146.6464 -1.3147% 0RUK None None% 0RYA 1631.0 -0.6094% 0RIH 171.3 0.9131% 0RIH 174.9 2.1016% 0R1O 186.0 9820.0% 0R1O None None% 0QFP None None% 0M2Z 298.3 -0.6495% 0VSO None None% 0R1I None None% 0QZI 474.5 0.6363% 0QZ0 220.0 0.0% 0NZF None None%

Verici Dx Plc

Healthcare GB VRCI

8.25GBP
-0.1(1.20%)

Last update at 2024-05-16T17:38:00Z

Day Range

8.128.50
LowHigh

52 Week Range

4.5319.00
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Income before tax -11.40700M -8.32983M -
Minority interest - - -
Net income -11.35900M -8.32983M -
Selling general administrative 10.50M 2.56M -
Selling and marketing expenses - - -
Gross profit - - -
Reconciled depreciation 0.64M 0.44M -
Ebit -11.45500M -8.32983M -2.39274M
Ebitda -10.76200M -7.89207M -
Depreciation and amortization 0.69M 0.44M -
Non operating income net other - - -
Operating income -11.45500M -8.32983M -
Other operating expenses 11.46M 8.51M -
Interest expense 0.00500M 0.00000M 0.00000M
Tax provision 0.00000M 0.00000M -
Interest income 0.05M - -
Net interest income 0.05M 0.00000M -
Extraordinary items - - -
Non recurring - - -
Other items - - -
Income tax expense -0.04800M - -
Total revenue 0.00000M 0.00000M -
Total operating expenses 11.46M 8.51M -
Cost of revenue - - -
Total other income expense net 0.05M - -
Discontinued operations - - -
Net income from continuing ops -11.40700M -8.32983M -
Net income applicable to common shares -11.40700M -8.32983M -7.10251M
Preferred stock and other adjustments - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Total assets 14.30M 13.79M 20.31M
Intangible assets 1.97M 2.01M 1.77M
Earning assets - - -
Other current assets - 0.66M 0.32M
Total liab 2.80M 1.80M 0.68M
Total stockholder equity 11.51M 11.98M 19.62M
Deferred long term liab - - -
Other current liab 1.14M 1.64M 0.21M
Common stock 0.22M 0.18M 0.18M
Capital stock 0.22M 0.18M 0.18M
Retained earnings -24.47200M -13.06484M -4.73501M
Other liab 0.54M - -
Good will - - -
Other assets - - -
Cash 9.80M 10.34M 17.75M
Cash and equivalents - - -
Total current liabilities 2.10M 1.80M 0.68M
Current deferred revenue -0.15600M - -
Net debt -9.64900M -10.33979M -17.67754M
Short term debt 0.16M - 0.07M
Short long term debt - 0.00000M 0.07M
Short long term debt total 0.16M - 0.07M
Other stockholder equity 35.76M 24.87M 24.18M
Property plant equipment 2.01M 0.79M 0.46M
Total current assets 10.32M 11.00M 18.07M
Long term investments - - -
Net tangible assets 9.54M 9.98M 17.86M
Short term investments - - -
Net receivables 0.52M 0.25M 0.12M
Long term debt - - -
Inventory - - -
Accounts payable 0.96M 0.16M 0.39M
Total permanent equity - - -
Noncontrolling interest in consolidated entity - - -
Temporary equity redeemable noncontrolling interests - - -
Accumulated other comprehensive income - - -
Additional paid in capital - - -
Common stock total equity - - -
Preferred stock total equity - - -
Retained earnings total equity - - -
Treasury stock - - -
Accumulated amortization - - -
Non currrent assets other - - -
Deferred long term asset charges - - -
Non current assets total 3.98M 2.79M 2.23M
Capital lease obligations 0.16M - -
Long term debt total - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Investments -1.30800M -0.96586M -
Change to liabilities 0.29M 1.15M 1.02M
Total cashflows from investing activities -1.30800M -0.96586M -0.23716M
Net borrowings - -0.07355M -0.07355M
Total cash from financing activities 12.67M -0.07355M 26.75M
Change to operating activities - - 0.80M
Net income -11.40700M -8.32983M -7.10251M
Change in cash -0.53500M -7.41130M 26.63M
Begin period cash flow 10.34M 17.75M -
End period cash flow 9.80M 10.34M 17.75M
Total cash from operating activities -10.06800M -6.33644M -1.28148M
Issuance of capital stock 13.07M 0.00000M -
Depreciation 0.64M 0.44M 0.29M
Other cashflows from investing activities - - -
Dividends paid - - -
Change to inventory - - -
Change to account receivables 0.14M -0.33097M -0.48484M
Sale purchase of stock - - -
Other cashflows from financing activities -0.39600M -0.96586M -1.43999M
Change to netincome 0.27M 0.74M 4.19M
Capital expenditures 1.31M 0.97M 0.04M
Change receivables - - -
Cash flows other operating - - -
Exchange rate changes - - -
Cash and cash equivalents changes - - -
Change in working capital 0.43M 0.81M -
Stock based compensation 0.32M 0.74M -
Other non cash items -0.04800M - -
Free cash flow -11.37600M -7.30230M -

Fundamentals

  • Previous Close 8.35
  • Market Cap16.18M
  • Volume251837
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-10.20600M
  • Revenue TTM0.02M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.05

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (GBP) Price (GBP) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
VRCI
Verici Dx Plc		 -0.1 1.20% 8.25 - - 851.60 3.00 637.86 -1.1703
IDHC
Integrated Diagnostics Holdings PLC		 -0.002 0.63% 0.32 0.18 12.89 0.0006 2.89 0.06 0.21
DXRX
Diaceutics PLC		 6.00 5.77% 110.00 - 19.72 3.52 1.85 2.71 17.28
AGL
ANGLE plc		 -0.75 3.23% 22.50 - - 18.87 0.88 5.81 -0.4917
LLAI
LungLife AI Inc		 -4.0 15.69% 21.50 - - 323.34 2.14 374.31 -2.4573

Reports Covered

Stock Research & News

View All

Profile

Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its lead products comprise Tutivia, a post-transplant test focused on acute rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection. The company also develops Protega, a peripheral blood-based test that aims to predict the risk of fibrosis and long-term graft failure. Verici Dx plc was incorporated in 2020 and is based in Penarth, the United Kingdom.

Verici Dx Plc

Avon House, Penarth, United Kingdom, CF64 2EZ

Key Executives

Name Title Year Born
Ms. Sara Barrington A.C.A., A.C.I.M. CEO & Exec. Director 1968
Mr. David M. Anderson Chief Financial Officer 1963
Mr. Salim Hamir F.C.A. Company Sec. NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions